SRRK - Scholar Rock Holding Corporation
| Previous Close | 14.95 |
| Open | 15.40 |
| Bid | 15.05 x 800 |
| Ask | 15.16 x 1100 |
| Day's Range | 14.48 - 15.40 |
| 52 Week Range | 13.09 - 30.00 |
| Volume | 182,881 |
| Avg. Volume | 111,418 |
| Market Cap | 393.393M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.40 |
| Earnings Date | Aug 6, 2019 - Aug 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 31.67 |
- Motley Fool•6 days ago
Why Carnival, Steelcase, and Scholar Rock Holding Slumped Today
Find out why these stocks missed the rally.
- Motley Fool•6 days ago
Why Scholar Rock Is Sinking Today
The good news? The cause of the drop should be a temporary issue.
- GlobeNewswire•7 days ago
Scholar Rock to Present at the 2019 BMO Prescriptions for Success Healthcare Conference
CAMBRIDGE, Mass., June 19, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•8 days ago
Scholar Rock Announces Proposed Public Offering of Common Stock
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it intends to offer and sell in an underwritten public offering 3,000,000 shares of its common stock. In addition, Scholar Rock has granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock. All of the shares are being offered by Scholar Rock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Scholar Rock intends to use the net proceeds from the offering to fund the SRK-015 program for the treatment of Spinal Muscular Atrophy (SMA), the SRK-181 program for the treatment of cancers that are resistant to checkpoint blockade therapies, preclinical activities for other pipeline programs, as well as for working capital and other general corporate purposes.
- GlobeNewswire•23 days ago
Scholar Rock Announces Positive Final Results from Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers
“We are pleased to be presenting the Phase 1 SRK-015 trial results at the upcoming Cure SMA annual conference as these data provide initial safety and mechanistic insights for SRK-015 and support our Phase 2 program,” said Yung Chyung, M.D., Chief Medical Officer of Scholar Rock. “The pharmacodynamic results from the Phase 1 trial offer initial proof-of-mechanism for Scholar Rock’s unique therapeutic approach of targeting the latent form of growth factors,” said Nagesh Mahanthappa, Ph.D., President and CEO of Scholar Rock.
- GlobeNewswire•29 days ago
Scholar Rock to Present at the Jefferies 2019 Global Healthcare Conference
CAMBRIDGE, Mass., May 28, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•last month
Scholar Rock Reports First Quarter 2019 Financial Results and Highlights Business Progress
Commenced patient enrollment and dosing in TOPAZ, the Phase 2 clinical trial for SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA) Presented additional preclinical data.
- Insider Monkey•2 months ago
Is Scholar Rock Holding Corporation (SRRK) A Good Stock To Buy?
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
- GlobeNewswire•2 months ago
Scholar Rock Announces Initiation of Patient Dosing in Phase 2 Trial of SRK-015 in Spinal Muscular Atrophy
Dosing of patients has commenced in TOPAZ, the Phase 2 clinical trial of SRK-015 in Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Preliminary PK/PD data from a subset of.
- GlobeNewswire•2 months ago
Scholar Rock Appoints Akshay Vaishnaw, M.D., Ph.D. to Its Board of Directors
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that Akshay Vaishnaw M.D., Ph.D. has been appointed to Scholar Rock’s Board of Directors, effective May 21, 2019 and that Timothy A. Springer, Ph.D. will transition to a role of scientific advisor to Scholar Rock. Dr. Springer will not be standing for re-election at the Company’s upcoming annual shareholder meeting.
- GlobeNewswire•2 months ago
Scholar Rock Announces Appointment of Lisa Amaya Price as Senior Vice President, Human Resources
CAMBRIDGE, Mass., April 11, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•3 months ago
Scholar Rock Presents Additional Preclinical Data Demonstrating a Highly Specific Inhibitor of TGFβ1 Activation Can Render Resistant Solid Tumors Vulnerable to PD1 Blockade and Drive Tumor Regression with Combination Therapy
Preclinical data presented at the American Association for Cancer Research annual meeting provide further support for the potential of SRK-181 to overcome primary resistance to.
- GlobeNewswire•3 months ago
Scholar Rock Reports Full Year 2018 Financial Results and Highlights Business Progress
Initiated and Progressed Phase 1 Clinical Trial of SRK-015 in Healthy Volunteers, Transitioning to a Clinical-Stage Company Presented Compelling Preclinical Data from the.
- GlobeNewswire•3 months ago
Scholar Rock to Develop Cancer Immunotherapy Product Candidate, SRK-181, a Selective Inhibitor of TGFβ1 Activation, to Overcome Checkpoint Inhibitor Resistance
Selective inhibition of TGFβ1 activation enables immune cell entry into the tumor microenvironment in preclinical models, demonstrating potential for overcoming a key mechanism.
- GlobeNewswire•4 months ago
Scholar Rock to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., March 06, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- GlobeNewswire•4 months ago
Scholar Rock Announces Positive Interim Results from Phase 1 Trial of SRK-015 in Healthy Volunteers and Updates on Future Development Plans
Favorable Safety Profile Across All Tested Doses Supports Initiation of a Phase 2 Trial in Patients with Spinal Muscular Atrophy (SMA)Pharmacodynamic Results Demonstrate Robust.
- Zacks•4 months ago
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review
FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.
- Simply Wall St.•6 months ago
Read This Before Selling Scholar Rock Holding Corporation (NASDAQ:SRRK) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales have Read More...
- Investopedia•6 months ago
Gilead Stock Breaks Out to Channel Resistance
Gilead Sciences shares posted gains on Thursday morning after Bistrol-Myers' acquisition of Celgene sent shares across the sector higher.
- GlobeNewswire•6 months ago
Scholar Rock to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 03, 2019 -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in.
- Motley Fool•6 months ago
Why Cabot Oil & Gas, Uxin, and Scholar Rock Holding Slumped Today
Several stocks simply lost momentum from past successes.
- Zacks•6 months ago
Biotech Stock Roundup: ALXN, ACOR Drugs' Get FDA Nod, AGEN up on GILD Deal
It was a busy week for the biotech sector with quite a few FDA approvals and some strategic partnerships.
- Zacks•6 months ago
Gilead Partners with Scholar Rock for Fibrotic Disease Drugs
Gilead Sciences (GILD) collaborates with Scholar Rock Holding Corporation for the development of fibrotic disease candidates.
- Benzinga•6 months ago
Raymond James: Gilead In NASH For The Long Haul
Gilead Sciences, Inc. (NASDAQ: GILD ) announced a strategic collaboration Wednesday with Scholar Rock Holding Corp (NASDAQ: SRRK ). Although not strictly a nonalcoholic steatohepatitis, or NASH, deal, ...
- Business Wire•6 months ago
Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
Gilead Sciences, Inc. (GILD) and Scholar Rock Holding Corporation (SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta (TGFβ) activation for the treatment of fibrotic diseases. Under the collaboration, Gilead has exclusive options to license worldwide rights to product candidates that emerge from three Scholar Rock TGFβ programs: inhibitors that target activation of latent TGFβ1 with high affinity and specificity, inhibitors that selectively target activation of latent TGFβ1 localized to extracellular matrix, and a third TGFβ discovery program. Scholar Rock is responsible for antibody discovery and preclinical research through product candidate nomination, after which, upon exercising the option for a program, Gilead will be responsible for the program’s preclinical and clinical development and commercialization.
